Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Cardiovascular disease in pregnancy

Cardiology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Chest pain, syncope, sustained arrhythmia, hypoxaemia, pulmonary oedema or sudden severe chest/back pain in pregnancy is not physiological: activate maternal emergency care with obstetric, cardiology, anaesthetic and critical-care teams and investigate without delaying necessary imaging.

Synopsis

Risk-stratify cardiovascular disease before and during pregnancy, recognise maternal emergencies and coordinate care through a Pregnancy Heart Team.

  • Assess known CVD before conception using mWHO 2.0 plus lesion-specific and individual factors.
  • Women with mWHO 2.0 class II-III or higher should be evaluated and managed by a Pregnancy Heart Team from pre-pregnancy through postpartum care.
  • mWHO 2.0 class IV indicates extremely high maternal and fetal risk; provide expert shared decision-making and discuss alternatives to pregnancy, not coercive care.
  • Normal pregnancy increases plasma volume, heart rate and cardiac output; these changes can unmask valve disease, cardiomyopathy, pulmonary hypertension or aortopathy.
  • Use ECG and echocardiography freely when indicated; do not withhold essential chest imaging or CT solely because of pregnancy.
  • ACE inhibitors and ARBs should be avoided when planning pregnancy and are contraindicated during pregnancy; DOACs are not used for pregnancy anticoagulation.
  • Haemodynamic risk often peaks around delivery and the early postpartum fluid shift, so the plan must extend beyond birth.

Key red flags

Aortic syndrome

Abrupt severe chest/back pain, pulse deficit or neurological signs in an aortopathy is an emergency.

Investigation priorities

01
12-lead ECG and rhythm monitoringFirst step

Assess chest pain, syncope, palpitations or known arrhythmia.

Management branches

FirstPre-pregnancy cardiovascular review

Known or suspected CVD, prior cardiotoxic therapy or important family/genetic cardiac history.

  1. Define diagnosis, functional status, ventricular/valve/aortic state, rhythm and previous pregnancy outcomes.
  2. Assign mWHO 2.0 risk and refer class II-III or higher to a Pregnancy Heart Team.
  3. Review every medicine for pregnancy and breastfeeding safety; replace ACE inhibitors/ARBs and plan anticoagulation where relevant.
  4. Discuss maternal and fetal risks, inheritance, contraception, timing and alternatives using shared decision-making.

Key medicines

LabetalolFor hypertension in pregnancy, start 100 mg orally twice daily; increase at weekly intervals as needed, up to 100 to 400 mg three times daily, maximum 2.4 g/day.Avoid or use specialist caution with asthma, bradycardia, heart block or decompensated heart failure; monitor maternal BP/heart rate and fetal growth.
Nifedipine modified releaseA typical starting dose is 10 mg orally every 12 hours, titrated to a maximum 40 mg every 12 hours for the referenced MR product.Use a modified-release product; headache, flushing and hypotension. Avoid grapefruit and account for CYP3A4 interactions; do not use short-acting nifedipine for uncontrolled rapid BP reduction.
Open full textbook →Answer 2 questionsCardiology check
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • ESC 2025 cardiovascular disease and pregnancy guidelinemWHO 2.0, Pregnancy Heart Team and disease-specific care.
  • RCOG cardiac disease and pregnancyUK multidisciplinary maternity context.
  • NICE NG133: hypertension in pregnancyNational antihypertensive selection.
  • MHRA: ACE inhibitors and ARBs in pregnancyRegulatory safety advice.
  • Labetalol 100 mg SmPCPregnancy dosing and cautions.
  • Nifedipress MR 10 mg SmPCProduct-specific 12-hour modified-release dosing and interactions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom